Hatch BioFund Management

Hatch BioFund focuses on early-stage life-science and health-technology companies, committing capital at seed and start-up rounds and following on through expansion when portfolio companies meet clinical or regulatory milestones. The firm invests across therapeutics, medical devices, diagnostics, and digital-health platforms. Its model is built on direct equity positions rather than fund-of-funds commitments, and it operates with a sector-concentrated mandate that excludes generalist technology or consumer investments.

The firm participates in syndicated rounds with other specialist healthcare investors, particularly those active in the Northeast corridor and major US biotech clusters. Its typical co-investor set includes other life-science-focused venture firms with deep domain expertise, enabling shared diligence on scientific claims and regulatory pathways. Hatch BioFund does not operate as a solo underwriter for the majority of its deals.

Hatch BioFund targets the earliest stages of company formation — seed and start-up — where capital is scarce and scientific risk is highest. It also participates in expansion and later-stage rounds for portfolio companies that have achieved clinical proof-of-concept or demonstrated a clear FDA pathway. The expansion capital comes from the same committed vehicle rather than a separate growth fund, keeping the firm's incentives aligned across the full company lifecycle.

The firm invests broadly across life sciences, with confirmed focus areas that include therapeutics, medical devices, diagnostics, and digital-health infrastructure. Hatch BioFund favors companies with intellectual property anchored in university research or founder-led discovery, and its diligence is weighted toward clinical-trial design and regulatory strategy rather than market-sizing exercises.